Sara A. Hurvitz, MD, of the University of California, Los Angeles, discusses the natural history and novel combinations for HER2-positive disease as well as predictive and prognostic markers for this type of breast cancer.
Xavier Pivot, MD, PhD, of the Paul Strauss Cancer Center, discusses final study findings comparing 6 and 12 months of trastuzumab in adjuvant early breast cancer (Abstract GS2-07).
Shoichiro Ohtani, MD, PhD, of Hiroshima City Hiroshima Citizens Hospital, discusses study findings on extending anastrozole to 10 years, which led to higher rates of disease-free survival and distant disease–free survival (Abstract GS3-04).
Andrew D. Seidman, MD, of Memorial Sloan Kettering Cancer Center, and Charles E. Geyer, MD, of Virginia Commonwealth University, discuss phase III study findings on ado-trastuzumab emtansine vs trastuzumab as adjuvant therapy in patients with early HER2-positive breast cancer with residual invasive disease after neoadjuvant chemotherapy and HER2-targeted treatment (Abstract GS1-10).
Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute, and Daniel F. Hayes, MD, of the University of Michigan Rogel Cancer Center debate whether all women with breast cancer and positive lymph nodes should receive chemotherapy.
Zaida Morante, MD, of the Instituto Nacional de Enfermedades Neoplasicas, discusses retrospective study findings showing the importance of starting adjuvant chemotherapy for people with triple-negative breast cancer within 30 days of surgery (Abstract GS2-05).
